SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics announced a $300 million public offering of common…

Spyre Therapeutics, Inc. · PRESS-RELEASE filed Apr 13, 2026 at 16:46 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 16:46 ET

Spyre Therapeutics announced a $300 million public offering of common stock, with underwriters expected to receive a 30-day option to purchase up to an additional $45 million in shares. The proceeds will be used for general corporate purposes, including funding clinical development programs in IBD and immune-mediated diseases.

  • Spyre Therapeutics is conducting a $300 million public offering of common stock.
  • Underwriters are expected to receive a 30-day option to purchase up to an additional $45 million in shares.
  • All shares are being sold by the company, indicating primary issuance and dilution to existing shareholders.
  • Proceeds will support clinical development and general corporate purposes.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access